Home » Newsletters » BioWorld Science

BioWorld Science

March 27, 2019

View Archived Issues

miR-183-5p/Erbin signaling pathway regulates proliferation and differentiation of AML cells

Human alpha-galactosidase mRNA therapy for the treatment of Fabry disease: preclinical results

ADC targets wild-type and mutated ALK

Synthetic lethal strategy for pancreatic cancer

An orchestrated nuclear phosphoinositide kinase complex regulates p53 stabilization

Obesity, insulin resistance bring on blood-brain barrier breakdown

Enrollment ongoing in phase II study of recombinant subunit tuberculosis vaccine GamTBvac

Lutris Pharma initiates phase I study of LUT-014 in patients with mCRC

Phase III ALLEVIATE study of reproxalap meets the primary and key secondary endpoint

New mutations found in a case of idiopathic hypogonadotropic hypogonadism

ONO-ST-468 suppresses excessive GH secretion in GHRH/arginine-induced GH hypersecretion model

FDA clears Selvita's IND application to conduct phase I study of SEL-120

NSD2 is a novel biomarker and potential epigenetic target for retinoblastoma

Topline data presented from phase II advanced liver cancer study of namodenoson

ALK-4290 demonstrates safety and improvement in BCVA score in patients with nAMD

Shanghai Meizer Pharmaceuticals patents ALK kinase receptor inhibitors

Roche discloses compounds binding E3 ubiquitin-protein ligase

Lysophosphatidic acid receptor 1 antagonists identified at Lilly

Amgen describes new Mcl-1 inhibitors

AcuraStem patents 1-phosphatidylinositol 3-phosphate 5-kinase inhibitors

Rosuzet approved in Japan for hypercholesterolemia and familial hypercholesterolemia

Progesterone found to predict prognosis of adrenocortical carcinoma

FDA approves Mayzent for relapsing forms of MS

Boronated analogues of pleuromutilins show promise for filarial infections in vivo

Revcovi approved in Japan for ADA deficiency

Phase II trial of Triplex for CMV complications in HSCT recipients meets primary endpoint

IMV reports preliminary phase II data for DPX-Survivac in ovarian cancer

NBE-Therapeutics describes antibody product targeting ROR1

AnGes obtains conditional approval in Japan for HGF plasmid in critical limb ischemia

Foscavir approved in Japan to treat HHV-6 encephalitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...